Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (RNAC)
Filing Type: Form 8-K (Current Report)
Report Date: August 6, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The Company announced its financial results for the second quarter of 2026. The full details are contained in a press release furnished as Exhibit 99.1 to this filing.
Key Financial Metrics
The provided filing text serves as a cover document referencing the announcement of results but does not contain specific numerical data. The following metrics are not disclosed in this text:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Note: Specific values for these metrics are not present in the provided 8-K text; they are referenced as being in the attached press release (Exhibit 99.1).
Material Changes
The filing text does not provide specific data to compare against the prior comparable period. No material changes in financial condition or operations are detailed within this document.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements are referenced as being part of the press release attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Verify the Company's cash runway and liquidity position as of June 30, 2026.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if there were any changes to the Company's financial guidance or operational outlook.